- DRAP asks all provinces to ensure docs prescribe medicines with their generic names.
- Drug Attorneys Discussion board president says docs and pharmaceutical firms violate drug regulatory legal guidelines.
- DRAP announcement comes after residents complained by way of the Prime Minister’s Efficiency Supply Unit (PMDU) in opposition to company-influenced brand-based prescription of medicines by docs.
LAHORE: All provinces have been requested by the Drug Regulatory Authority of Pakistan (DRAP) to ensure docs prescribe medicines with their generic names in the private and non-private sectors.
DRAP gave the directions after public complaints on the PM’s residents’ portal in opposition to pharmaceutical firms and docs’ collusion to tear off folks by way of prescription and sale of costlier medicines underneath a model identify.
A letter was written to the well being secretaries of all 4 provinces, Azad Jammu Kashmir and Gilgit-Baltistan and the Islamabad commissioner by DRAP Pharmacy Providers Director Dr Abdur Rasheed.
Learn extra: Life-saving medication turn into 15% costlier after coronavirus lockdown
It mentioned residents had complained by way of the Prime Minister’s Efficiency Supply Unit (PMDU) in opposition to company-influenced brand-based prescription of medicines by docs in authorities and personal sectors.
“This practice adds to the economic burden of the country and puts financial load on patients due to purchase of pricier brands. Such practice is also against the Code of Ethics for medical and dental practitioners,” the letter learn.
DRAP, subsequently, directed the well being authorities throughout Pakistan to take mandatory measures to advertise generic prescriptions by docs and discourage the observe of incentivised prescription.
The Drug Act 1976, in its Part 7 “Registration of Drugs”, Clause-8, says that single-ingredient medication (containing one energetic ingredient) shall be registered typically by their generic names, whereas compound medication (containing a couple of energetic ingredient) shall be registered typically by their proprietary names.
Learn extra: Govt approves as much as 262% hike in costs of almost 100 medicines
Drug Attorneys Discussion board President Noor Mahar mentioned docs and pharmaceutical firms collude and are concerned within the unethical observe of writing even single-ingredient medication with their manufacturers names in violation of the regulatory legislation.
As an example, he named a model drugs manufactured with Amlodipine salt for coronary heart sufferers is being offered at Rs460, whereas identical drug with the one other model identify is on the market for Rs49.